Indication:for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.dosage:adult- the recommended starting dose is 0.5 mg qid or 1 mg bid (2 capsules of 0.5 mg twice a day) and can be increased to 4 times daily.mechanism of action :the mechanism by which anagrelide reduces blood platelet count is still under investigation. studies in patients support a hypothesis of dose-related reduction in platelet production resulting from a decrease in megakaryocyte hypermaturation. in blood withdrawn from normal volunteers treated with anagrelide, a disruption was found in the postmitotic phase of megakaryocyte development and a reduction in megakaryocyte size and ploidy.